ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 115 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q2 2020. The put-call ratio across all filers is 1.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $667,621 | +9.4% | 26,130 | +22.8% | 0.28% | +2.6% |
| Q2 2023 | $610,138 | -20.9% | 21,274 | -33.9% | 0.27% | -26.7% |
| Q1 2023 | $771,091 | +117.8% | 32,169 | +43.0% | 0.37% | +42.1% |
| Q2 2022 | $354,000 | +40.5% | 22,499 | +326.1% | 0.26% | +31.2% |
| Q3 2021 | $252,000 | +16.1% | 5,280 | -17.7% | 0.20% | +26.8% |
| Q2 2021 | $217,000 | -50.7% | 6,417 | -37.4% | 0.16% | -52.1% |
| Q3 2020 | $440,000 | -17.9% | 10,248 | -10.7% | 0.33% | -20.2% |
| Q2 2020 | $536,000 | -22.7% | 11,478 | -77.5% | 0.41% | -51.1% |
| Q1 2020 | $693,000 | +22.7% | 51,021 | -1.8% | 0.84% | +103.4% |
| Q4 2019 | $565,000 | +43.0% | 51,982 | +35.2% | 0.41% | +26.7% |
| Q3 2019 | $395,000 | +9.4% | 38,461 | +0.7% | 0.33% | +42.4% |
| Q2 2019 | $361,000 | – | 38,207 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SEVEN EIGHT CAPITAL, LP | 46,819 | $2,031,000 | 0.47% |
| Orbimed Advisors | 1,206,886 | $49,844,000 | 0.47% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 25,000 | $1,033,000 | 0.40% |
| ARK Investment Management | 3,331,889 | $137,607,000 | 0.27% |
| FEDERATED HERMES, INC. | 3,203,000 | $132,284,000 | 0.26% |
| MGO ONE SEVEN LLC | 26,990 | $1,114,000 | 0.19% |
| Koss-Olinger Consulting, LLC | 20,000 | $826,000 | 0.14% |
| Jump Financial, LLC | 35,400 | $1,462,000 | 0.14% |
| Graham Capital Management, L.P. | 74,262 | $3,067,000 | 0.14% |
| New England Research & Management, Inc. | 6,005 | $248,000 | 0.14% |